These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 29943290)

  • 1. Physiologically based pharmacokinetic-quantitative systems toxicology and safety (PBPK-QSTS) modeling approach applied to predict the variability of amitriptyline pharmacokinetics and cardiac safety in populations and in individuals.
    Tylutki Z; Mendyk A; Polak S
    J Pharmacokinet Pharmacodyn; 2018 Oct; 45(5):663-677. PubMed ID: 29943290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanistic Physiologically Based Pharmacokinetic (PBPK) Model of the Heart Accounting for Inter-Individual Variability: Development and Performance Verification.
    Tylutki Z; Mendyk A; Polak S
    J Pharm Sci; 2018 Apr; 107(4):1167-1177. PubMed ID: 29175411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physiologically-based pharmacokinetic models: approaches for enabling personalized medicine.
    Hartmanshenn C; Scherholz M; Androulakis IP
    J Pharmacokinet Pharmacodyn; 2016 Oct; 43(5):481-504. PubMed ID: 27647273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bayesian Population Physiologically-Based Pharmacokinetic (PBPK) Approach for a Physiologically Realistic Characterization of Interindividual Variability in Clinically Relevant Populations.
    Krauss M; Tappe K; Schuppert A; Kuepfer L; Goerlitz L
    PLoS One; 2015; 10(10):e0139423. PubMed ID: 26431198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling to Predict the Impact of CYP2C9 Genetic Polymorphisms, Co-Medication and Formulation on the Pharmacokinetics and Pharmacodynamics of Flurbiprofen.
    Loisios-Konstantinidis I; Cristofoletti R; Jamei M; Turner D; Dressman J
    Pharmaceutics; 2020 Nov; 12(11):. PubMed ID: 33147873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a Whole-Body Physiologically Based Pharmacokinetic Approach to Assess the Pharmacokinetics of Drugs in Elderly Individuals.
    Schlender JF; Meyer M; Thelen K; Krauss M; Willmann S; Eissing T; Jaehde U
    Clin Pharmacokinet; 2016 Dec; 55(12):1573-1589. PubMed ID: 27351180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Ethnicity-Specific Hepatic Microsomal Scaling Factor, Liver Weight, and Cytochrome P450 (CYP) 1A2 Content on Physiologically Based Prediction of CYP1A2-Mediated Pharmacokinetics in Young and Elderly Chinese Adults.
    Li GF; Zheng QS; Yu Y; Zhong W; Zhou HH; Qiu F; Wang G; Yu G; Derendorf H
    Clin Pharmacokinet; 2019 Jul; 58(7):927-941. PubMed ID: 30767128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model of the histone deacetylase (HDAC) inhibitor vorinostat for pediatric and adult patients and its application for dose specification.
    Moj D; Britz H; Burhenne J; Stewart CF; Egerer G; Haefeli WE; Lehr T
    Cancer Chemother Pharmacol; 2017 Nov; 80(5):1013-1026. PubMed ID: 28988277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human Pharmacokinetic and CYP3A Drug-Drug Interaction Prediction of GDC-2394 Using Physiologically Based Pharmacokinetic Modeling and Biomarker Assessment.
    Yu J; Tang F; Ma F; Wong S; Wang J; Ly J; Chen L; Mao J
    Drug Metab Dispos; 2024 Jul; 52(8):765-774. PubMed ID: 38811156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physiologically based pharmacokinetic (PBPK) modeling for prediction of celecoxib pharmacokinetics according to CYP2C9 genetic polymorphism.
    Kim YH; Kang P; Cho CK; Jung EH; Park HJ; Lee YJ; Bae JW; Jang CG; Lee SY
    Arch Pharm Res; 2021 Jul; 44(7):713-724. PubMed ID: 34304363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Promises of Quantitative Proteomics in Precision Medicine.
    Prasad B; Vrana M; Mehrotra A; Johnson K; Bhatt DK
    J Pharm Sci; 2017 Mar; 106(3):738-744. PubMed ID: 27939376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physiologically based pharmacokinetic/pharmacodynamic modeling to evaluate the absorption of midazolam rectal gel.
    Zhu J; Zhao Y; Wang L; Zhou C; Zhou S; Chen T; Chen J; Zhang Z; Zhu Y; Ding S; Shao F
    Eur J Pharm Sci; 2021 Dec; 167():106006. PubMed ID: 34520836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physiologically-Based Pharmacokinetic (PBPK) Modeling Providing Insights into Fentanyl Pharmacokinetics in Adults and Pediatric Patients.
    Kovar L; Weber A; Zemlin M; Kohl Y; Bals R; Meibohm B; Selzer D; Lehr T
    Pharmaceutics; 2020 Sep; 12(10):. PubMed ID: 32977559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Challenges Associated With Applying Physiologically Based Pharmacokinetic Modeling for Public Health Decision-Making.
    Tan YM; Worley RR; Leonard JA; Fisher JW
    Toxicol Sci; 2018 Apr; 162(2):341-348. PubMed ID: 29385573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative Modeling Analysis Demonstrates the Impact of CYP2C19 and CYP2D6 Genetic Polymorphisms on the Pharmacokinetics of Amitriptyline and Its Metabolite, Nortriptyline.
    Koh A; Pak KC; Choi HY; Ryu S; Choi SE; Kim KS; Bae KS; Lim HS
    J Clin Pharmacol; 2019 Apr; 59(4):532-540. PubMed ID: 30452773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A four-compartment PBPK heart model accounting for cardiac metabolism - model development and application.
    Tylutki Z; Polak S
    Sci Rep; 2017 Jan; 7():39494. PubMed ID: 28051093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of in vitro data in developing a physiologically based pharmacokinetic model: Carbaryl as a case study.
    Yoon M; Kedderis GL; Yan GZ; Clewell HJ
    Toxicology; 2015 Jun; 332():52-66. PubMed ID: 24863738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of physiologically based pharmacokinetic and physiologically based pharmacodynamic models for applications in toxicology and risk assessment.
    Andersen ME
    Toxicol Lett; 1995 Sep; 79(1-3):35-44. PubMed ID: 7570672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PBPK models in risk assessment--A focus on chloroprene.
    DeWoskin RS
    Chem Biol Interact; 2007 Mar; 166(1-3):352-9. PubMed ID: 17324392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of the Utility of Physiologically-based Pharmacokinetic Model for prediction of Pharmacokinetics in Chinese and Japanese Populations.
    Yu Y; Lin J; Muto C; Li Y; Mori Y; Mittapalli RK; Tse S; Liu J; Ge BK; Liu J
    Int J Med Sci; 2021; 18(16):3718-3727. PubMed ID: 34790045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.